Related Experiment Video
Updated: Jan 28, 2026

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
Anti-β2GPI/β2GPI complexes induce platelet activation and promote thrombosis via p38MAPK: a pathway to targeted
Wenjing Zhang1, Caijun Zha1, Xiumin Lu1
1Department of Laboratory Diagnosis, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Anti-β2 glycoprotein I (anti-β2GPI) antibodies are important contributors to the development of thrombosis. Anti-β2GPI antibody complexes with β2GPI are well known to activate monocytes and endothelial cells via the intracellular NF-kB pathway with prothrombotic implications. By contrast, the interaction of anti- β2GPI/β2GPI complexes with platelets has not been extensively studied. The p38 mitogen-activated protein kinase (MAPK) pathway has been recognized to be an important intracellular signaling pathway in the coagulation cascade and an integral component of arterial and venous thrombosis. The present study reveals that levels of anti- β2GPI/β2GPI complexes in sera are positively associated with p38MAPK phosphorylation of platelets in thrombotic patients. Furthermore, SB203580 inhibits anti-β2GPI/β2GPI complex-induced platelet activation. Thrombus formation decreased in p38MAPK-/- mice after treatment with anti-β2GPI/β2GPI complexes. In conclusion, p38MAPK may be a treatment target for anti-β2GPI antibody-associated thrombotic events.
Anti-β2 glycoprotein I (anti-β2GPI) antibodies are important contributors to the development of thrombosis. Anti-β2GPI antibody complexes with β2GPI are well known to activate monocytes and endothelial cells via the intracellular NF-kB pathway with prothrombotic implications. By contrast, the interaction of anti- β2GPI/β2GPI complexes with platelets has not been extensively studied. The p38 mitogen-activated protein kinase (MAPK) pathway has been recognized to be an important intracellular signaling pathway in the coagulation cascade and an integral component of arterial and venous thrombosis. The present study reveals that levels of anti- β2GPI/β2GPI complexes in sera are positively associated with p38MAPK phosphorylation of platelets in thrombotic patients. Furthermore, SB203580 inhibits anti-β2GPI/β2GPI complex-induced platelet activation. Thrombus formation decreased in p38MAPK-/- mice after treatment with anti-β2GPI/β2GPI complexes. In conclusion, p38MAPK may be a treatment target for anti-β2GPI antibody-associated thrombotic events.
Related Concept Videos
Anaphase Promoting Complex
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Eukaryotic Promoter Region
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
Gene Therapy
Venous Thrombosis I: Introduction

